Orchard Therapeutics — Conference Presentation (January 2019)
25 slides from Orchard Therapeutics's conference presentation, Jan 7, 2019
Slide 1: Mark Rothera, President & CEO, January 9, 2019
Mark Rothera President & Chief Executive Officer January 9, 2019 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Certain information set forth in this presentation and in statements made orally during this presentation contains “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but
Slide 3: Global Fully Integrated Biotech Dedicated to Transforming the Lives of Patients with Rare Diseases
Global Fully Integrated Biotech Dedicated to Transforming the Lives of Patients with Rare Diseases Through Innovative Gene Therapies Singular focus on autologous ex-vivo gene therapy for rare diseases
Slide 4: Orchard's Lead Programs Show Transformative Potential
Orchard’s Lead Programs Show Transformative Potential Source: UCLA study; n=20 Overall survival data Gross motor function measure (GMFM) GMFM total score in late infantile (LI) MLD at 24 months post OTL-200 vs. natural history Severe infection rate Pre Gene Therapy Post Gene Therapy OTL-101 for ADA
Slide 5: Orchard Now a Leading Global Gene Therapy Company
Orchard Now a Leading Global Gene Therapy Company 2 clinical stage programs 5 pre-clinical programs 55 employees ~$320M post Series B London, UK Single CA site Primarily investors 1 commercial product 5 clinical stage programs 10 pre-clinical programs ~180 employees Executive leadership team in plac
Slide 6: Global Leadership in Gene Therapy for Rare Diseases
Global Leadership in Gene Therapy for Rare Diseases Deep pipeline of five clinical-stage gene therapies & potential to treat CNS disorders Over 150 patients treated, with promising clinical data and durable long-term effects Three submissions for product approvals anticipated over the next three yea
Slide 7: Deep Pipeline of Gene Therapies with Transformative Potential
Strimvelis® OTL-101 OTL-103 OTL-102 OTL-3003 OTL-200 OTL-201 OTL-202 Deep Pipeline of Gene Therapies with Transformative Potential Preclinical Clinical proof of concept Registrational trial Commercialization Designations Neurometabolic disorders Hemoglobinopathies Primary immune deficiencies MLD (me
Slide 8: Over 150 Patients Treated with Orchard's Autologous Ex Vivo Gene Therapies
Over 150 Patients Treated with Orchard’s Autologous Ex Vivo Gene Therapies 1 Patients treated in the development phase, including in clinical trials and under pre-approval access (defined as any form of pre-approval treatment outside of a company-sponsored clinical trial, including, but not limited
Slide 9: Delivering Therapeutic Genes to Multiple Physiological Systems
Delivering Therapeutic Genes to Multiple Physiological Systems Platelets Granulocyte MLD MPS-IIIA MPS-IIIB ADA-SCID WAS X-CGD CD34+ Hematopoietic stem cells (HSCs) TDBT WAS Viral vector carrying therapeutic gene Macrophage / Microglia Central nervous system Immune system Red blood cell and platelet
Slide 10: Numerous Data and Clinical Milestones Anticipated in 2019
Numerous Data and Clinical Milestones Anticipated in 2019 OTL-200 (MLD) 2 & 3 year follow-up fresh formulation (n=20) Cryo formulation engraftment data (n=3) Clinical Trial Initiations & Other Milestones 3 Registrational Clinical Trial Data Sets OTL-101 (ADA-SCID) 2 year follow-up fresh formulation
Slide 11: Neurometabolic Disorders
Orchard therapeutics Neurometabolic Disorders
Slide 12: Delivery of Proteins to the Brain Unlocks Potential to Treat Neurometabolic Diseases
Delivery of Proteins to the Brain Unlocks Potential to Treat Large Number of Neurometabolic Diseases Source: Capotondo et al. PNAS 2012;109:15018-15023; Brain of a wildtype mouse transplanted with GFP-LV transduced HSPCs after Busulfan conditioning Green = GFP (green fluorescent protein); blue = nuc
Slide 13: Devastating Neurometabolic Diseases with No Approved Treatment Options
Devastating Neurometabolic Diseases with No Approved Treatment Options 1 ARSA: arylsulfatase-A; 2 Mahmood (2010); 3 Sergijenko (2013) and Boelens (2010); 4 Buhrman (2013) SGSH: N-sulfoglycosamine sulfohydrolase; NAGLU: N-acetyl-alpha-glucosaminidase Disease Overview / Symptoms Deficiency in the ARSA
Slide 14: OTL-200 for MLD: Significant Improvements in Motor Function
OTL-200 for MLD: Significant Improvements in Motor Function MAA Submission Expected in 2020 (followed by BLA) Treatment difference (OTL-200 – untreated): 66.1% (LI) and 45% (EJ) respectively Source: clinical study report (CSR) of 05 December 2017 Late infantile MLD - GMFM Total Score at 24 months po
Slide 15: OTL-201 and OTL-202 (MPS-IIIA and MPS-IIIB): Preclinical Proof of Concept
~80% decrease in heparan sulfate vs. MPS-IIIA wild type 11% enzyme expression vs. wild type OTL-201 and OTL-202 (MPS-IIIA And MPS-IIIB): Preclinical Proof of Concept CTA Submission for MPS-IIIA Expected in 2019 Sergijenko et al, Mol. Ther. 2013, 21(10), 1938-1949 Increased enzyme expression in the b
Slide 16: Primary Immune Deficiencies (PIDs)
Primary Immune Deficiencies (PIDs)
Slide 17: Life Threatening Inherited Immune Disorders: ADA-SCID, WAS and X-CGD
Life Threatening Inherited Immune Disorders: ADA-SCID, WAS and X-CGD 1 Oszahin (2008); Albert (2011); 2 Dupuis-Girod (2003); 3 van den Berg et. al, PLoS One. 2009;4(4):e5234. Disease Overview / Symptoms Deficiency in ADA enzyme T, B, and NK cell dysfunction Recurrent and life-threatening severe infe
Slide 18: OTL-101 for ADA-SCID: Registrational Trial Supports Transformative Potential
OTL-101 for ADA-SCID: Registrational Trial Supports Transformative Potential BLA Submission Expected in 2020 (followed by MAA) Data from registrational 2-year fresh cell product; n=20 Overall Survival Event-free Survival 100% overall survival (n=20) 100% event-free survival (n=20) 62 patients treate
Slide 19: OTL-103 for WAS: Evidence of Consistent and Durable Efficacy
OTL-103 for WAS: Evidence of Consistent and Durable Efficacy Cryo Trial to Initiate 2019; BLA/MAA submission in 2021 Data based on interim clinical study report of 10 Jan 2017; figures reflect data as of the cut-off date of 29 April 2016 Bleedings per patient per year Severe infections per patient p
Slide 20: OTL-102 for X-CGD: Evidence of Sustained Neutrophil Activity in Patients
OTL-102 for X-CGD: Evidence of Sustained Neutrophil Activity in Patients Proof of Concept Established in December 2018 Data provided by Great Ormond Street Hospital, Boston Children Hospital, NIH and UCLA; unaudited data as of 07-May-2018; † patient deceased from advanced disease Excludes data from
Slide 21: CMO Infrastructure Established for Launch of First Three Cryopreserved Gene Therapy Products
CMO Infrastructure Established for Launch of First Three Cryopreserved Gene Therapy Products Isolate hematopoietic stem cells (HSCs) Gene-modify HSCs with lentiviral vector Cryopreserve HSC product Manufacture disease-specific lentiviral vector Collect blood or bone marrow Thaw and infuse product Sh
Slide 22: Enhancing Our Ability to Supply Ex Vivo Gene Therapy Programs
New facility will provide significant additional CGMP manufacturing capacity for lentiviral vector and cryopreserved cell therapy products Enhancing Our Ability to Supply Ex Vivo Gene Therapy Programs Drives efficiencies and scalability in terms of lentiviral vector and drug product development Comp
Slide 23: Lead Indications Represent Potential >$2B Market Opportunity
Lead Indications Represent Potential >$2B Market Opportunity Orchard Retains Full Commercial Rights to All Indications in All Markets Data based on Company estimates derived from published literature. Prevalence Incidence 2,200 – 6,300 2,900 – 4,700 > $2B market opportunity based predominantly on in
Slide 24: Numerous Data and Clinical Milestones Anticipated in 2019
Numerous Data and Clinical Milestones Anticipated in 2019 OTL-200 (MLD) 2 & 3 year follow-up fresh formulation (n=20) Cryo formulation engraftment data (n=3) Clinical Trial Initiations & Other Milestones 3 Registrational Clinical Trial Data Sets OTL-101 (ADA-SCID) 2 year follow-up fresh formulation
Slide 25: Transforming the lives of patients through innovative gene therapies
Transforming the lives of patients through innovative gene therapies www.orchard-tx.com
Orchard Therapeutics — Conference Presentation (January 2019) on 6ix